#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Blood iron increased Ornithine transcarbamoylase deficiency Neuroblastoma Heritable pulmonary arterial hypertension Factor IX deficiency Factor VIII deficiency Chondrosarcoma Parkinson's disease Drug eruption Frostbite Non-Hodgkin's lymphoma refractory Undifferentiated sarcoma Acute promyelocytic leukaemia Cervix carcinoma Neuroendocrine tumour of the lung More trials…

    Learn about Rare Diseases

    Lysosomal storage disorder – Life with Disease Undifferentiated sarcoma – Basic Information Haemolytic uraemic syndrome Bronchopulmonary dysplasia Familial haemophagocytic lymphohistiocytosis Marginal zone lymphoma refractory – Diagnostics Prolymphocytic leukaemia – Trials in Disease IgA nephropathy – Trials in Disease Haemophilia A without inhibitors – Basic Information Piriformis syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Liraglutide Dsimc Oxcarbazepine Regn7257 Mometasone Furoate Inclisiran Sodium Odm-212 Doxazosin Alanyl Glutamine Amsacrine NADOFARAGENE FIRADENOVEC Brexucabtagene Autoleucel Boserolimab ANOC-001 Pitolisant Onasemnogene Abeparvovec Relugolix Tebipenem Pivoxil Hydrobromide Pravastatin Sodium Levodropropizine More therapies…

    Learn about Your Condition

    Hairy cell leukaemia Testicular germ cell cancer Acute on chronic liver failure Primary hyperaldosteronism Limb reduction defect Nocturia Large cell lung cancer Basal cell carcinoma Dilated cardiomyopathy Transplantation complication Endometrial cancer stage I Neuropathic arthropathy Immunodeficiency Colon cancer Acquired haemophilia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Niepubliczny Zakład Opieki Zdrowotnej Vivamed Jadwiga…

Niepubliczny Zakład Opieki Zdrowotnej Vivamed Jadwiga Miecz

Ul. Zamiejska 17, Warsaw, 03-580, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of MT-501 in patients with active Crohn’s Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Belgium Bulgaria Croatia Czechia Germany Italy +2

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia France +8

  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Obefazimod
    Belgium Czechia France Germany Hungary Italy +5

  • Long-term safety study of tulisokibart in adults with Crohn’s disease or ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Czechia France Hungary Poland

  • A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Vixarelimab
    • Mercaptopurine
    • Azathioprine
    Belgium Czechia France Germany Greece Italy +1

  • A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn’s disease or ulcerative colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Austria Belgium Bulgaria Croatia Czechia France +8

  • Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate-to-Severe Ulcerative Colitis

    Not recruiting

    2 1
    Austria Belgium Bulgaria Croatia Czechia France +6
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!